CA Patent

CA2989975C — Drospirenone-based contraceptive for a female patient affected with excess weight

Assigned to Laboratorios Leon Farma SA · Expires 2021-10-12 · 5y expired

What this patent protects

Drospirenone as the sole contraceptive ingredient comprised in a daily active dosage unit in an amount of at least 3 mg for use as a contraceptive for a female patient affected with obesity.

USPTO Abstract

Drospirenone as the sole contraceptive ingredient comprised in a daily active dosage unit in an amount of at least 3 mg for use as a contraceptive for a female patient affected with obesity.

Drugs covered by this patent

Patent Metadata

Patent number
CA2989975C
Jurisdiction
CA
Classification
—
Expires
2021-10-12
Drug substance claim
No
Drug product claim
No
Assignee
Laboratorios Leon Farma SA
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.